Top 10 Pharmaceutical Companies in India 2025

Introduce with this article about the Top 10 Pharmaceutical Companies in India in 2025, ranked based on innovation, market presence, and contribution to the healthcare sector.

India is a global powerhouse in the pharmaceutical industry, renowned for its high-quality, affordable medicines and cutting-edge research. As the world’s largest supplier of generic drugs, the Indian pharmaceutical sector continues to expand, driven by technological advancements, government initiatives, and increasing demand for healthcare solutions. In 2025, the industry is more competitive than ever, with companies focusing on innovation, global expansion, and sustainable growth. This article highlights the Top 10 Pharmaceutical Companies in India in 2025, showcasing their impact on both domestic and international markets.

Key Trends in 2025

-Expansion in biosimilars and biologics

-Increased focus on specialty medicines and high-value generics

-Stronger compliance with global regulatory standards (US FDA, EMA, WHO-GMP)

-Growth in domestic API production to reduce dependency on imports

-Adoption of digital health solutions and AI-driven drug discovery

-India’s pharmaceutical sector is set to reach $130 billion by 2030, driven by innovation and exports to

over 200 countries, including the United States, Europe, and emerging markets.

Listed the Top 10 Pharmaceutical Companies in India

1. Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Limited, commonly known as Sun Pharma, is a leading Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. Founded in 1983 by Dilip Shanghvi, the company has grown to become the largest pharmaceutical entity in India and ranked as the fourth-largest specialty generic pharmaceutical company in the world.

Headquarters: Plot No. 201 B/1, Sun House, Western Express Highway, Goregaon (East), Mumbai, Maharashtra, 400063, India.

Manufacturing Facilities: The company operates 43 manufacturing facilities across the globe, with significant operations in India, the United States, Asia, Africa, Australia, and Europe. These facilities are equipped to produce a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs).

Total Products: Offers a broad portfolio of more than 2,000 high-quality molecules covering multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids and therapeutic classes including: Psychiatry, Neurology, Cardiology, Diabetology, Gastroenterology, Ophthalmology, Nephrology, Urology, Dermatology, Gynecology, Respiratory, Oncology, Dental, Nutritionals

Export Facilities: Approximately 70% of Sun Pharma’s revenue is derived from international markets, with the United States and India being its largest markets. The company’s products are available in over 100 countries worldwide.

Total Revenue: In the Fiscal Year 2024 reported consolidated total revenue from operations of ₹484.97 billion (approximately US$5.76 billion). The company’s consistent growth trajectory has solidified its position as a market leader in the pharmaceutical industry.

Growth Rate: Achieved a revenue growth of 10.51% Year-on-Year in FY2024 compared to the previous fiscal year.

Market Share: Holds an 8.5% market shares in the Indian pharmaceutical market, ranking number one as per the AIOCD AWACS MAT March 2024 report.

Flagship Products: The Company’s flagship products span a variety of therapeutic areas, including: notable products such as Ilumya (tildrakizumab) for moderate-to-severe plaque psoriasis, Cequa (cyclosporine ophthalmic solution) for dry eye disease, and Odomzo (sonidegib) for advanced basal cell carcinoma.

Accreditations: Sun Pharma’s manufacturing facilities have received accreditations from major global regulatory agencies, including: U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), Therapeutic Goods Administration (TGA) of Australia

2. Divi’s Laboratories Ltd.

Divi’s Laboratories Limited, established in 1990, is a prominent Indian pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs) and intermediates. Headquartered in Hyderabad, Telangana, the company has expanded its operations to include multiple manufacturing facilities and research centers across India.

Headquarters: Divi Towers, Cyber Hills, Gachibowli, Hyderabad, Telangana, India.

Manufacturing Facilities: Divi’s Laboratories operates several state-of-the-art manufacturing units:

-Choutuppal Unit: Located in Lingojigudem village, Choutuppal mandal, Yadadri Bhuvanagiri district, Telangana.

-DC SEZ Unit: Also situated in Lingojigudem village, Choutuppal mandal, Yadadri Bhuvanagiri district, Telangana.

-Export Oriented Unit: Based in Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh.

-Divi’s Pharma SEZ Unit: Located in Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh.

-DSN SEZ Unit: Situated in Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh.

-DCV SEZ Unit: Also in Chippada village, Bheemunipatnam mandal, Visakhapatnam district, Andhra Pradesh.

Total Products: Divi’s Laboratories offers a diverse portfolio of over 150 products, including APIs and intermediates, catering to various therapeutic segments such as anti-inflammatory, anti-diabetic, cardiovascular, and central nervous system disorders.

Export Facilities: The company has a robust global presence, exporting to over 95 countries. Approximately 87% of its total sales revenue is derived from exports, with major markets including North America, Europe, and the Asia-Pacific region. Notably, exports to the US and Europe constitute about 71% of the total revenue.

Total Revenue: In the nine months ending December 31, 2024, Divi’s Laboratories reported a consolidated total income of ₹70.41 billion, reflecting significant growth compared to ₹58.04 billion, in the same period of the previous year.

Growth Rate: The company has demonstrated robust financial performance, with a notable 64.53% increase in net profit for the quarter ended December 2024, reaching ₹5.89 billion compared to ₹3.58 billion in the corresponding quarter of the previous year.

Market Share: Divi’s Laboratories holds a significant position in the global pharmaceutical industry, being India’s fourth-largest publicly listed pharmaceutical company by market capitalization. It commands a substantial share in the global API market, particularly in products like Naproxen, Dextromethorphan, and Gabapentin, with market shares ranging between 60% and 85%.

Flagship Products: The company’s flagship products include: Naproxen (a widely used nonsteroidal anti-inflammatory drug (NSAID), Dextromethorphan (common cough suppressant), Gabapentin (Used to treat neuropathic pain and epilepsy), Pregabalin (Prescribed for neuropathic pain and as an adjunct therapy for partial seizures), Methylamine (An intermediate used in various pharmaceutical applications).

Accreditations: Divi’s Laboratories’ manufacturing facilities are accredited by major global regulatory authorities, including: (FDA) U.S. Food and Drug Administration, (WHO) World Health Organization, (EMA) European Medicines Agency.

Top 20 Best-selling Drugs Globally in 2025

Top 10 Pharmaceutical Companies in USA 2024

3. Cipla Ltd.

Cipla Limited, established in 1935, is a prominent Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in developing and manufacturing a wide range of pharmaceutical products, including generic drugs, active pharmaceutical ingredients (APIs), and over-the-counter medications.

Headquarters: Mumbai, Maharashtra, India.

Manufacturing Facilities: Cipla operates 47 state-of-the-art manufacturing facilities across six countries, producing over 1,500 products in more than 50 dosage forms.

Total Products: The company’s portfolio includes over 1,500 products across 65 therapeutic categories.

Export Facilities: Cipla has a global presence, exporting to more than 80 countries worldwide.

Total Revenue: For the fiscal year ending March 31, 2024, Cipla reported a total income of ₹265.20 billion (approximately US$3.1 billion), reflecting a 14% increase from the previous fiscal year.

Growth Rate: The company’s revenue grew by 14% year-over-year in FY2024.

Market Share: Cipla holds a 5.4% market share in the Indian pharmaceutical market, ranking 3rd overall. It is the leader in the respiratory segment with a 24.6% market share.

Flagship Products: Cipla’s flagship products include:Foracort (A leading inhaler in the Indian market),Nicotex (A nicotine replacement therapy for smoking cessation),Cofsils (Lozenges for sore throat relief), Cipremi (Remdesivir, used for COVID-19 treatment).

Accreditations: Cipla’s manufacturing facilities are approved by major international regulatory agencies, including: U.S. Food and Drug Administration (USFDA),European Directorate for the Quality of Medicines (EDQM),World Health Organization (WHO), Therapeutic Goods Administration (TGA), Australia, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

4. Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd., headquartered in Ahmedabad, Gujarat, India, is a prominent player in the pharmaceutical industry. Established in 1959 by U. N. Mehta, the company has expanded its footprint to over 40 countries, offering a diverse range of pharmaceutical products.

Headquarters: Ahmedabad, Gujarat, India.

Manufacturing Facilities: The company operates multiple state-of-the-art manufacturing plants across India, including locations in Dahej (Gujarat), Pithampur (Madhya Pradesh), Indrad (Mehsana, Gujarat), Baddi (Himachal Pradesh), and Sikkim. These facilities are designed to meet both domestic and international demand.

Total Products: Torrent Pharma offers a wide array of products across various therapeutic segments, including cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective, and pain management. The company has a robust portfolio with over 2,000 product registrations globally.

Export Facilities: With a presence in more than 40 countries, Torrent Pharma has established a strong international footprint. The company operates fully owned subsidiaries in several countries, including the United States, Germany, Brazil, Russia, the Philippines, and Canada, facilitating efficient export operations.

Total Revenue: In the fiscal year ending March 31, 2024, Torrent Pharmaceuticals reported consolidated sales of ₹105.62 billion, marking an 11.6% increase from the previous year. The net profit for the same period was ₹1,656 crore, reflecting a 33% growth.

Growth Rate: The company’s consistent financial performance indicates a robust growth trajectory, with significant year-over-year increases in both revenue and net profit.

Market Share: Torrent Pharma is ranked 5th in the Indian Pharmaceutical Market (IPM) and boasts 21 brands among the top 500 in the IPM. Notably, 16 of these brands have revenues exceeding ₹100 crore.

Flagship Products: Among its diverse product range, “Shelcal 500,” a calcium supplement, stands out as a flagship product, widely recognized and trusted in the market.

Accreditations: Torrent Pharmaceuticals’ manufacturing facilities are accredited by major global regulatory authorities, including the U.S. Food and Drug Administration (USFDA), reflecting the company’s commitment to maintaining high-quality standards in its operations.

Heumann Pharma GmbH & Co Generica KG, Germany

Torrent Pharma GmbH, Germany

Torrent do Brasil Ltda., Brazil

ZAO Torrent Pharma, Russia

Torrent Pharma Inc., United States

Torrent Pharma Philippines Inc., Philippines

Torrent Pharma Canada Inc., Canada

Torrent Pharma UK, United Kingdom

5. Mankind Pharma Ltd.

Mankind Pharma Limited, established in 1991 by brothers Ramesh C. Juneja and Rajeev Juneja, has evolved into one of India’s leading pharmaceutical companies. Headquartered in Delhi, the company offers a diverse range of products across various therapeutic areas, including antibiotics, gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma operates 25 manufacturing facilities and six R&D centers within India. Notably, the company derives approximately 97% of its operating revenue from the domestic market, positioning it as the fourth-largest pharmaceutical company in India by domestic sales.

Headquarters: Okhla Phase III, Delhi, India.

Manufacturing Facilities: Operates 25 manufacturing facilities across India, located in Himachal Pradesh, Sikkim, Rajasthan, Andhra Pradesh, Maharashtra, and Uttarakhand.

Total installed capacity of 40.77 billion units per annum, producing a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, and more.

Total Products: Offers a diverse portfolio of over 1,000 products across various therapeutic areas such as anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, and more.

Export Facilities: Exports products to over 40 countries, including the United States, Latin America, Southeast Asia, Africa, and the Middle East. In Q2 FY25, export revenue grew by 57% year-on-year, reaching ₹281 crore.

Total Revenue: For the fiscal year ending March 2024, reported revenue of ₹150.00 billion, a 25% increase from the previous fiscal year.

Growth Rate: Achieved a compound annual growth rate (CAGR) of 15% from FY2023 to FY2026, driven by new product launches and market expansion.

Market Share: As of December 2024, holds a 4.8% share in the Indian Pharmaceutical Market (IPM), up from 4.4% in March 2024.

Flagship Products:

Manforce Condoms: Leading brand in the male condom category with a 30.2% market share.

Prega News: Popular pregnancy test kit.

Unwanted-72: Emergency contraceptive pill.

Nurokind: Neuroprotector containing methylcobalamin combinations.

Telmikind: Telmisartan combinations used to treat hypertension.

Accreditations: Manufacturing facilities have obtained approvals and certifications from regulatory bodies including the Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (USFDA).Facilities are compliant with World Health Organization Good Manufacturing Practices (WHO GMP) and Pharmaceutical Inspection Co-operation Scheme (PIC/S) guidelines.

6. Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Laboratories Ltd., established in 1984 by Dr. K. Anji Reddy, is a prominent Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in manufacturing and marketing a diverse range of pharmaceutical products, including generic medications, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) drugs.

Headquarters: Hyderabad, Telangana, India.

Manufacturing Facilities: Dr. Reddy’s operates 22 manufacturing facilities worldwide, producing a variety of pharmaceutical formulations and APIs.

Total Products: The company’s portfolio includes over 190 medications and 60 active pharmaceutical ingredients (APIs).

Export Facilities: Dr. Reddy’s has a global presence, exporting products to over 70 countries, with a significant market share in regions like North America, Europe, and emerging markets.

Total Revenue: For the fiscal year ending March 31, 2024, Dr. Reddy’s reported consolidated revenues of ₹ 279.16 billion, reflecting a 13.54% growth compared to the previous year.

Growth Rate: The company achieved a revenue growth rate of 13.54% in FY2024, driven by strong performances in global generics across North America, Europe, and emerging markets.

Market Share: In the Indian pharmaceutical market, Dr. Reddy’s holds the 6th position, with a market share of approximately 4.2%.

Flagship Products: Some of Dr. Reddy’s top brands in India include:Nise (Nimesulide),Omez (Omeprazole), Stamlo, Stamlo Beta, Enam, Atocor, Razo These products cater to various therapeutic areas such as gastroenterology, cardiology, and pain management.

Accreditations: Dr. Reddy’s has received several notable accreditations:

Featured in the Dow Jones Sustainability World Index for 2023, retaining its place in the Emerging Markets Index for the 8th consecutive year.

Awarded ‘Gold Medal’ status by EcoVadis for sustainability efforts.

Upgraded to a ‘BBB’ rating by MSCI ESG Ratings.

Received Golden Peacock Awards for Corporate Social Responsibility and Excellence in Corporate Governance in 2023.

standards.

7. Lupin Ltd.

Founded in 1968 by Desh Bandhu Gupta, Lupin has evolved into a global pharmaceutical powerhouse headquartered in Mumbai. The company’s diverse portfolio encompasses generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). Lupin’s therapeutic focus areas include cardiology, diabetology, respiratory, anti-infectives, gastroenterology, central nervous system, and women’s health.

Headquarters: Mumbai, Maharashtra, India.

Manufacturing Facilities: Lupin operates 15 state-of-the-art manufacturing sites across India and internationally, including locations in the United States, Mexico, and Brazil.

Total Products: The company’s diverse portfolio encompasses over 870 marketed drugs, addressing various therapeutic areas such as cardiovascular, anti-diabetic, respiratory, anti-infective, gastrointestinal, central nervous system, and women’s health.

Export Facilities: Lupin’s products are distributed in over 100 countries, with a significant presence in regions like North America, Europe, Asia Pacific, Latin America, and the Middle East.

Total Revenue: For the fiscal year ending March 31, 2024, Lupin reported consolidated revenue from operations of ₹200,108 million, marking a 20.2% increase over the previous fiscal year.

Growth Rate: The company achieved a robust double-digit growth rate exceeding 20% in FY2024, surpassing its previous sales peak in FY2017.

Market Share: Lupin holds the 3rd position in the U.S. generic pharmaceuticals market by prescriptions and ranks 7th in the Indian pharmaceutical market.

Flagship Products: Key products include treatments for tuberculosis, diabetes, asthma, and cardiovascular diseases. Notably, Lupin is a global leader in anti-tuberculosis medications and has a strong presence in the cephalosporins segment.

Accreditations: Lupin’s manufacturing facilities are accredited by major global regulatory agencies, including the U.S. Food and Drug Administration (FDA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

8. Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd., formerly known as Cadila Healthcare Ltd., is a prominent Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. Established in 1952 by Ramanbhai Patel, the company has grown to become a significant player in the global pharmaceutical industry.

Headquarters: Ahmedabad, Gujarat, India.

Manufacturing Facilities: Zydus operates multiple manufacturing facilities across India, including locations in Gujarat, Goa, Maharashtra, Sikkim, and Himachal Pradesh. Internationally, the company has production sites in Brazil and the United States.

Total Products: The company’s diverse portfolio encompasses over 850 marketed drugs, addressing various therapeutic areas such as gastrointestinal, cardiovascular, respiratory, pain management, oncology, inflammation, neurology, and women’s health.

Export Facilities: Zydus Lifesciences maintains a strong global presence, exporting products to markets in the United States, Europe, South Africa, Japan, Brazil, and numerous other emerging markets.

Total Revenue: For the fiscal year ending March 31, 2024, the company reported revenue from operations of ₹195.474 billion, reflecting a 13% increase over the previous year.

Growth Rate: In FY24, Zydus Lifesciences achieved a net profit growth of 97% year-over-year, amounting to ₹38,595 million.

Market Share: Within the Indian pharmaceutical sector, Zydus Lifesciences holds a substantial market share, ranking among the top 10 pharmaceutical companies in the country.

Flagship Products: Notable products in Zydus’s portfolio include:

Lipaglyn (Saroglitazar): Used for treating diabetic dyslipidemia.

Exemptia (Adalimumab biosimilar): A biosimilar for autoimmune diseases.

Vivitra (Trastuzumab biosimilar): Employed in oncology treatments.

Bryxta (Bevacizumab biosimilar): Another key oncology therapeutic.

Accreditations: Zydus Lifesciences’s manufacturing facilities are accredited by several international regulatory authorities, including the U.S. Food and Drug Administration (USFDA), European Medicines Agency (EMA), and the World Health Organization (WHO), ensuring compliance with global quality

9. Aurobindo Pharma Ltd.

Aurobindo Pharma Limited, established in 1986 by P.V. Ramprasad Reddy and K. Nityananda Reddy, began operations in 1988–89 with a single unit manufacturing semi-synthetic penicillin in Puducherry.

Headquarters: The company is headquartered in HITEC City, Hyderabad, Telangana, India.

Manufacturing Facilities: Aurobindo Pharma operates 29 manufacturing and packaging facilities globally, including 26 in India, 1 in the United States, 1 in Brazil, and 1 in Portugal.

Export Facilities: The company exports its products to over 150 countries, with a significant presence in the United States and Europe.

Total Products: Aurobindo Pharma has a diverse product portfolio, including over 870 marketed drugs.

Total Revenue: In the financial year 2023–24, the company reported a consolidated revenue of ₹29,002 crore (approximately $3.5 billion).

Growth Rate: The company has demonstrated consistent growth, with a 17% year-on-year increase in revenue for the financial year 2023–24.

Market Share: Aurobindo Pharma holds a significant market share in the U.S. generic pharmaceutical market, being the largest supplier by prescription volume as per IQVIA data for the year ending March 31, 2024.

Flagship Products: Aurobindo Pharma’s flagship products span various therapeutic areas, including:

Antibiotics: Semi-synthetic penicillins and cephalosporins.

Anti-Retrovirals (ARVs): Leading position in the HIV treatment segment.

Cardiovascular (CVS): Beta-blockers, ACE inhibitors, and anti-platelets.

Central Nervous System (CNS): Anti-depressants and anti-Alzheimer’s medications.

Gastroenterology: Proton pump inhibitors and anti-ulcer drugs.

Anti-Diabetics: Oral hypoglycemics.

Anti-Allergics: Antihistamines and related products.

Accreditations: The company’s manufacturing facilities are approved by leading regulatory agencies, including the U.S. Food and Drug Administration (USFDA), European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory Agency (MHRA), Japan Pharmaceuticals and Medical Devices Agency (PMDA), World Health Organization (WHO), Health Canada, South Africa Medicines Control Council (MCC), and Brazil’s National Health Surveillance Agency (ANVISA).

10. Alkem Laboratories Ltd.

Alkem Laboratories Ltd. is a prominent Indian multinational pharmaceutical company founded in 1973 by Samprada Singh and Basudeo Narayan Singh, Alkem began as a small chemist shop in Patna, Bihar. Over the decades, it has evolved into one of India’s leading pharmaceutical firms.

Headquarters: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai, Maharashtra, 400013, India.

Manufacturing Facilities: Alkem operates 21 manufacturing facilities across India and the United States. These facilities are compliant with cGMP guidelines and have received approvals from major regulatory authorities, including the US FDA, UK MHRA, and WHO-Geneva.

Total Products: Alkem boasts a diverse portfolio of over 800 brands, covering major therapeutic segments such as anti-infective, gastroenterology, pain management, anti-diabetic, cardiology, dermatology, and neurology/CNS. Notable flagship products include Clavam, Pan, Pan-D, and Taxim-O, which rank among the top 50 pharmaceutical brands in India.

Export Facilities: With a presence in over 40 countries, Alkem generates approximately 29% of its revenue from international markets. The company’s global footprint includes significant operations in the United States, Australia, South-East Asia, the UK, Russia-CIS, and Africa.

Total Revenue: (FY 2023-24) ₹126,676 million, a 9.2% year-over-year increase.

Profit After Tax (PAT): ₹17,958 million, reflecting an 82.5% growth.

EBITDA: ₹22,455 million, up by 39.5%.

Net Cash Position: ₹35.5 billion.

Growth Rate: In FY 2023-24, Alkem achieved a 5.4% growth in domestic sales and a 10.2% increase in its U.S. business.

Market Share: The company has consistently ranked among the top ten pharmaceutical companies in India and, for the first time, secured the second position in the Indian Pharmaceutical Market (IPM) during the first half of FY 2024-25.

Flagship Products: The company’s flagship products include Clavam, Pan, Pan-D, and Taxim-O, all of which rank among India’s top 50 pharmaceutical brands.

Accreditations: Alkem’s manufacturing facilities have been inspected and approved by leading regulatory bodies, including: US FDA, UK MHRA, TGA-Australia, ANVISA-Brazil, WHO-Geneva, SAHPRA-South Africa, TPD-Health Canada, PPB-Kenya, NDA-Uganda, MOH-Sudan, INVIMA-Colombia, TFDA-Tanzania, BfArM-Germany.

The Indian pharmaceutical industry is on an impressive growth trajectory, playing a crucial role in global healthcare. The top 10 pharmaceutical companies in India in 2025 stand out due to their innovation, regulatory compliance, and commitment to improving patient outcomes. As the sector evolves with advancements in biotechnology, digital health, and personalized medicine, these companies are set to shape the future of pharmaceuticals, reinforcing India’s position as a global pharma leader.